In addition to our HBV pipeline, we are developing a pipeline focused on Non-HBV Assets that leverage our RNA interference (RNAi) therapeutics and expertise in Lipid Nanoparticle (LNP) technology. RNAi and LNP technology has the potential to generate new therapeutics that take advantage of the body’s own natural processes to silence disease causing genes, or more specifically, to eliminate specific gene-products from the cell. Our LNP technology represents the most widely adopted delivery technology in RNAi. We will continue to support the clinical development of TKM-PLK1 and determine the best strategies for optimizing the value of the remaining assets. We also see significant value in the collaborations Arbutus has established to date, and will continue to work closely with, and support, our partners using our RNAi technology.
Our management team has significant experience developing and commercializing drug candidates targeting infectious liver diseases, including HCV. We are applying to our HBV programs, the same innovative thinking that members of our management team have successfully applied to developing a cure for HCV and to advancing LNP technology into clinical trials. We are dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, and to maximizing the value of our Non-HBV Assets.